Sanctuary Advisors LLC Invests $1.10 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sanctuary Advisors LLC acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 13,711 shares of the medical equipment provider’s stock, valued at approximately $1,101,000.

Several other large investors have also modified their holdings of LNTH. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Lantheus by 5.6% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 35,528 shares of the medical equipment provider’s stock worth $2,203,000 after acquiring an additional 1,894 shares during the period. Wellington Management Group LLP raised its holdings in Lantheus by 7.9% in the fourth quarter. Wellington Management Group LLP now owns 446,905 shares of the medical equipment provider’s stock valued at $27,708,000 after buying an additional 32,859 shares during the period. Greenwood Capital Associates LLC purchased a new position in Lantheus in the fourth quarter valued at approximately $354,000. PNC Financial Services Group Inc. raised its holdings in Lantheus by 14.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider’s stock valued at $596,000 after buying an additional 1,202 shares during the period. Finally, Nomura Holdings Inc. raised its holdings in Lantheus by 105.3% in the fourth quarter. Nomura Holdings Inc. now owns 20,678 shares of the medical equipment provider’s stock valued at $1,282,000 after buying an additional 407,507 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Stock Up 3.7 %

LNTH stock opened at $112.19 on Friday. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $7.79 billion, a P/E ratio of 18.39 and a beta of 0.50. The firm has a 50 day simple moving average of $104.20 and a 200-day simple moving average of $89.09.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same period in the previous year, the business posted $1.40 EPS. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

LNTH has been the topic of several research reports. Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a report on Thursday, July 25th. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a report on Thursday, August 1st. Leerink Partners raised their price target on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Finally, Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Transactions at Lantheus

In other Lantheus news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares of the company’s stock, valued at $2,047,402.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,322 shares of company stock valued at $2,731,150. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.